Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Celgene Corporation.

Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell Therapy


Release Date: August 30, 2018
Expiration Date: August 30, 2019
Media: Internet - based

Activity Overview

This activity, Advances inTM Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell Therapy, will focus on the evolution of chimeric antigen receptor (CAR)-modified T cells and the role of CAR T-cell therapy in patients with multiple myeloma (MM). The modules in this activity will include brief written summaries of the remarkable changes in MM therapy, the continuing need for new therapeutic approaches, and the evolving role of CAR T cells in the treatment paradigm for patients with MM. The expert faculty interviews will provide a clinical perspective to guide viewers on potential applications of CAR T-cell therapy to practice, as well as areas for future clinical investigation.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Celgene Corporation.
 

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational program is directed toward community oncologists, medical oncologists, and hematologists who treat patients with MM. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the treatment of MM are also invited to participate in the activity

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Explain the rationale behind the clinical development of CAR T-cell therapy for the treatment of MM, especially relapsed/refractory disease
  2. Compare and contrast the mechanism of action of CAR T-cell therapy against traditional MM treatment
  3. Summarize recent data and study designs of early-phase clinical trials concerning the application of CAR T-cell strategies in the management of relapsed/refractory MM
  4. Implement appropriate monitoring and management techniques to mitigate different treatment-related toxicities that may manifest in patients who receive CAR T-cell therapies

 

Faculty, Staff, and Planners' Disclosures

Faculty

Nikhil Munshi
Nikhil Munshi, MD
Professor of Medicine, Harvard Medical School
Director, Basic and Correlative Sciences
Associate Director
Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA

Disclosure: Consultant: Celgene, Amgen, Janssen Biotech Inc., Merck & Co., Pfizer Inc., Takeda, Oncopep, Inc.; Stock/Shareholder: Oncopep, Inc.; Other Support: Oncopep, Inc. (owner)

Noopur Raje
Noopur Raje, MD
Associate Professor of Medicine
Harvard Medical School
Director, Multiple Myeloma Center
Massachusetts General Hospital
Boston, MA

Disclosure: Grant/Research Support: AstraZeneca; Consultant: Amgen, BMS, Celgene, Janssen, Merck, Takeda

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse™ Recaps

1 of 3

New Approaches for Unmet Medical Needs In Multiple Myeloma

The online CME activity, Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell Therapy, features clinical data summaries and video interviews with Nikhil Munshi, MD, and Noopur Raje, MD, with a focus on the development of chimeric antigen receptor (CAR)-modified T cells in patients with multiple myeloma (MM). Throughout the interviews, the faculty discuss new data and provide perspectives on how the technology and application of CAR T cells continue to evolve.

This first of 3 PER Pulse™ Recaps focuses on the need for new mechanisms of action for patients with relapsed/refractory MM and the potential for CAR T cells in this setting.

  • Treatment of patients with MM has advanced significantly in the past 2 decades, with the development of proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies resulting in 5-year survival rates of approximately 50%. Nevertheless, a cure remains elusive, with relapses still occurring, even after treatment with highly active combination approaches.
  • An emerging therapeutic approach in hematologic malignancies is CAR T cells, which consists of a patient’s own T cells that have been re-engineered to express a CAR construct to direct the cells to cell-surface antigens. The CAR T cell then directly kills the tumor cell.
  • In patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma, CAR T cells directed to the CD19 antigen have been approved, with clinical trials ongoing in these and other hematologic malignancies. In MM, initial research has focused on the B-cell maturation antigen and is the focus of this activity.

2 of 3

Early Clinical Data With CAR T Cells in Patients With Relapsed/Refractory MM

The online CME activity, Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell Therapy, features clinical data summaries and video interviews with Nikhil Munshi, MD, and Noopur Raje, MD, with a focus on the development of chimeric antigen receptor (CAR)-modified T cells in patients with multiple myeloma (MM). Throughout the interviews, the faculty discuss new data and provide perspectives on how the technology and application of CAR T cells continue to evolve.

This second of 3 PER Pulse™ Recaps focuses on early-phase clinical data with B-cell maturation antigen–targeted CAR T cells in patients with relapsed/refractory MM.

  • In a phase I trial, bb2121 was investigated in 43 patients with a median of 7 to 8 prior regimens. In the subgroup of patients who received >150 x 106 CAR T cells, the overall response rate was 95.5%, including a complete response (CR) or stringent CR in 50% of patients. Measurable residual disease (MRD) negativity was achieved in 16 of 16 evaluable patients; in this group, the median progression-free survival (PFS) was 17.7 months. The median PFS in the overall cohort was 11.8 months.
  • A separate CAR T-cell construct, LCAR-B38M, was evaluated in 57 patients who received a median of 3 prior lines of therapy. Patients achieved an ORR of 88%, including a CR in 74%; MRD negativity was achieved in 68%. The median PFS was 15 months.
  • The incidence of cytokine release syndrome (CRS) so far in patients with MM has trended lower than that seen in patients with acute lymphoblastic leukemia and non-Hodgkin lymphoma, with grade ≥3 CRS seen in <10% of patients in these trials.

3 of 3

BCMA-Targeted Agents in Development

The online CME activity, Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell Therapy, features clinical data summaries and video interviews with Nikhil Munshi, MD, and Noopur Raje, MD, with a focus on the development of chimeric antigen receptor (CAR)-modified T cells in patients with multiple myeloma (MM). Throughout the interviews, the faculty discuss new data and provide perspectives on how the technology and application of CAR T cells continue to evolve.

This third of 3 PER Pulse™ Recaps focuses on B-cell maturation antigen (BCMA)-targeted agents in clinical development.

  • Although initial data with CAR T cells has been encouraging, additional trials are ongoing to confirm these results. The phase III KarMMa-3 trial is being carried out to compare bb2121 with standard triplet regimens in patients with 2 to 4 prior regimens. JNJ-68284528, a derivative of LCAR-B38M, is being further investigated in a phase I/II trial of patients who have received ≥3 prior lines of therapy. Other BCMA-targeted agents under investigation include JCARH125 and P-BCMA-101.
  • In addition to CAR T cells, antibody-based approaches are being investigated using BCMA as a target. The bispecific T-cell engager construct AMG 420 is being investigated in a phase I trial enrolling patients with ≥3 prior lines of therapy, including a proteasome inhibitors, an immunomodulatory agent, and a CD38-targeted antibody. Additionally, the antibody-drug conjugate GSK2857916 is being investigated in several early-phase trials in patients with relapsed/refractory MM.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
2728293031
Filter By